Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
INNOVENT BIO Slips 7%+ on First Day of Blue Chip Inclusion; 7 Innovative Products Added to China's NRDL
Recommend 9 Positive 24 Negative 10 |
||||
|
||||
|
INNOVENT BIO (01801.HK), being included in the HSI today (8th), opened up by 1.1%, reaching a high of HK$93.15 in early trade, before sharply reversing to a decline. The latest morning print showed HK$85, down 7.61%, with a turnover of HK$3.221 billion. The company announced last night (7th) that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List of China (NRDL). This list features a new indication of TYVYT, SYCUME, Limertinib, Dupert, DOVBLERON, Retsevmo, and Jaypirca. The updated NRDL will be officially effective from January 1, 2026. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
